SMRI Awarded Trial Detail
Trial Detail
GrantID06TGF-911
Primary Drug / InterventionL-Theanine
Dosage400 mg
Secondary Drug / Intervention 
Dosage 
Other Drug / Intervention 
Dosage 
IllnessSchizophrenia
Sample Size60
Trial DesignDouble-blind, randomized, placebo-controlled
Duration of Study Period for Each Subject8 weeks
Outcome MeasurementsPANNS, CGI, ANS, CDSS, HAM-A, SUMD, GAF, the Talbieh Brief Distress Inventory, the State/Trait Anxiety Inventory, QLS, Q-LES-Q, ESRS, BARS, CANTAB
ResultsSixty (60) patients with schizophrenia or schizoaffective disorder were randomized to L-theanine 400 mg/day for 8 weeks as an adjunct medication. Those on L-theanine had a significant improvement in anxiety, PANSS-positive, and general psychopathology symptoms.
PublicationRitsner MS, Miodownik C, Ratner Y et al., L-Theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study, J Clin Psychiatry 2010;71:1-9.
 
PI NameMichael Ritsner
DegreeMD,
Center 
InstitutionSha'ar Menashe Mental Health Center
Address Line 1Mobile Post Hefer 38814
Address Line 2 
City or TownHadera
State or Province 
Zip or Postal Code38814
CountryIsrael
Email Addressritsner@shaar-menashe.org.il